Back to Browse Journals » Vascular Health and Risk Management » Volume 9

Linagliptin as add-on therapy to insulin for patients with type 2 diabetes

Authors von Websky K, Reichetzeder C, Hocher B

Received 8 August 2013

Accepted for publication 24 September 2013

Published 1 November 2013 Volume 2013:9 Pages 681—694


Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 2

Karoline von Websky, Christoph Reichetzeder, Berthold Hocher

Institute of Nutritional Science, University of Potsdam, Potsdam-Rehbrücke, Germany

Abstract: Type 2 diabetes mellitus (T2DM) is a highly prevalent, progressive disease that often is poorly controlled. The combination of an incretin-based therapy and insulin is a promising approach to optimize the management of glycemic control without hypoglycemia and weight gain. Linagliptin, a recently approved oral dipeptidyl peptidase-4 inhibitor, has a unique pharmacological profile. The convenient, once-daily dosing does not need adjustment in patients with hepatic and/or renal impairment. In clinical studies linagliptin shows an important reduction of blood glucose with an overall safety profile similar to that of placebo. So far, the combination of linagliptin and insulin has been tested in three major clinical studies in different populations. It has been shown that linagliptin is an effective and safe add-on therapy to insulin in patients with T2DM. The efficacy and safety of this combination was also shown in vulnerable, elderly T2DM patients and in patients with T2DM and renal impairment. Favorable effects regarding the counteraction of hypoglycemia make linagliptin especially interesting as an add-on therapy to insulin. This review aims to present the existing clinical studies on the efficacy and safety of linagliptin as add-on therapy to insulin in patients with T2DM in the context of current literature. Additionally, the possible advantages of linagliptin as an add-on therapy to insulin in relation to cardiovascular safety, patient-centered therapy and the prevention of hypoglycemia, are discussed.

Keywords: incretin, dipeptidyl peptidase-4, glucagon like peptide-1, glycemic control, renal impairment, hypoglycemia

Download Article [PDF] View Full Text [HTML] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at:

Readers of this article also read:

Effects of exercise timing on sleep architecture and nocturnal blood pressure in prehypertensives

Fairbrother K, Cartner B, Alley JR, Curry CD, Dickinson DL, Morris DM, Collier SR

Vascular Health and Risk Management 2014, 10:691-698

Published Date: 12 December 2014

Low perfusion index affects the difference in glucose level between capillary and venous blood

Acar N, Ozcelik H, Cevik AA, Ozakin E, Yorulmaz G, Kebapci N, Bilge U, Bilgin M

Therapeutics and Clinical Risk Management 2014, 10:985-991

Published Date: 20 November 2014

Risk of Essure microinsert abdominal migration: case report and review of literature

Ricci G, Restaino S, Di Lorenzo G, Fanfani F, Scrimin F, Mangino FP

Therapeutics and Clinical Risk Management 2014, 10:963-968

Published Date: 17 November 2014

Serum lipid profile and correlates in newly presenting Nigerians with arterial hypertension

Adamu UG, Okuku GA, Oladele CO, Abdullahi A, Oduh JI, Fasae AJ

Vascular Health and Risk Management 2013, 9:763-768

Published Date: 3 December 2013

Vitamin E tocotrienol supplementation improves lipid profiles in chronic hemodialysis patients

Daud ZAM, Tubie B, Sheyman M, Osia R, Adams J, Tubie S, Khosla P

Vascular Health and Risk Management 2013, 9:747-761

Published Date: 28 November 2013

Changes in LDL-C levels and goal attainment associated with addition of ezetimibe to simvastatin, atorvastatin, or rosuvastatin compared with titrating statin monotherapy

Foody JM, Toth PP, Tomassini JE, Sajjan S, Ramey DR, Neff D, Tershakovec AM, Hu H, Tunceli K

Vascular Health and Risk Management 2013, 9:719-727

Published Date: 15 November 2013